gossypol and sorafenib

gossypol has been researched along with sorafenib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Dai, X; He, F; Lian, J; Ni, Z; Smith, AR; Su, C; Xu, L	1

Other Studies

2 other study(ies) available for gossypol and sorafenib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Molecular cancer therapeutics, 2012, Volume: 11, Issue:2 Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gossypol; Humans; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Time Factors; Xenograft Model Antitumor Assays	2012

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.

Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gossypol; Humans; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Time Factors; Xenograft Model Antitumor Assays

2012